Dr Reddy's fails one more US FDA test

Company's shares fall 4.4% to Rs 2,720, a 31-month low

In another setback to drug major Dr Reddy’s Laboratories’ (DRL’s) remediation effort, its oncology formulations facility at Duvvada in Visakhapatnam has got a long and adverse rap from the US Food and Drug Administration (FDA).

This particular rap is termed Form 483. The FDA issues it when an inspection of a unit reveals various objectionable deviations from its rules and standards. It was issued (“it has 13 observations, which we are addressing,” the company said, without details) after a new audit of the plant in question that was concluded on Thursday.

This is the second unit of Dr Reddy’s that has failed